WALTHAM, Mass. & VIENNA--(BUSINESS WIRE)--Mar. 5, 2018--
Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company
focused on applying monoclonal antibody immunotherapies to address
serious infectious diseases, announced today that CEO René Russo,
PharmD, BCPS, will present a company overview at the 38th
Annual Cowen and Company Health Care Conference on March 12, 2018, at
12:00 p.m. ET.
A webcast of the presentation will be available on the Arsanis website
under “Events and Presentations” or can be accessed at http://wsw.com/webcast/cowen46/asns/.
The webcast will be archived for 30 days following the live presentation.
Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on
applying monoclonal antibody (mAb) immunotherapies to address serious
infectious diseases. A deep understanding of the pathogenesis of
infection, paired with access to some of the most advanced mAb discovery
techniques and platforms available today, has positioned Arsanis to
build and advance a pipeline of novel mAbs with multiple mechanisms of
action and high potency against their intended targets. The company’s
lead clinical program, ASN100, is aimed at serious Staphylococcus
aureus infections and is being evaluated in a Phase 2 clinical trial
for the prevention of S. aureus pneumonia in high-risk,
mechanically ventilated patients. In addition to ASN100, its preclinical
pipeline is comprised of mAbs targeting multiple serious bacterial and
viral pathogens, including respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with
European research and preclinical development operations headquartered
in Vienna, Austria (Arsanis Biosciences GmbH).
For more information, please visit the Arsanis website at www.arsanis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180305005420/en/
Source: Arsanis, Inc.
Ten Bridge Communications
Chief Operating and Chief Financial Officer